<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: financial condition", fill: "#e68fac"},
{source: "2: financial condition", target: "2: operations could", fill: "#e68fac"},
{source: "2: operations could", target: "2: materially adversely affected by", fill: "#e68fac"},
{source: "2: financial condition", target: "3: additional risks", fill: "#c9dc87"},
{source: "3: additional risks", target: "3: presently known", fill: "#c9dc87"},
{source: "3: presently known", target: "3: the Company ", fill: "#c9dc87"},
{source: "3: the Company ", target: "3: immaterial may also impair", fill: "#c9dc87"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#c9dc87"},
{source: "3: additional risks", target: "4: Obtaining ", fill: "#ffbcd9"},
{source: "4: Obtaining ", target: "4: conditions may delay", fill: "#ffbcd9"},
{source: "4: conditions may delay", target: "4: prevent completion", fill: "#ffbcd9"},
{source: "4: prevent completion", target: "4: merger with", fill: "#ffbcd9"},
{source: "4: merger with", target: "4: Boston Scientific Corporation", fill: "#ffbcd9"},
{source: "4: Obtaining ", target: "11: Completion ", fill: "#fbceb1"},
{source: "11: Completion ", target: "11: also conditioned upon approval", fill: "#fbceb1"},
{source: "11: also conditioned upon approval", target: "11: transaction by", fill: "#fbceb1"},
{source: "11: transaction by", target: "11: advisories", fill: "#fbceb1"},
{source: "11: advisories", target: "11: concerning", fill: "#fbceb1"},
{source: "11: concerning", target: "11: defibrillator", fill: "#fbceb1"},
{source: "11: defibrillator", target: "11: malfunctions", fill: "#fbceb1"},
{source: "11: malfunctions", target: "11: adversely", fill: "#fbceb1"},
{source: "11: adversely", target: "11: operations", fill: "#fbceb1"},
{source: "11: Completion ", target: "13: second half", fill: "#c3b091"},
{source: "13: second half", target: "13: various implantable", fill: "#c3b091"},
{source: "13: various implantable", target: "13: defibrillator", fill: "#c3b091"},
{source: "13: defibrillator", target: "13: pacemaker system field actions", fill: "#c3b091"},
{source: "13: pacemaker system field actions", target: "13: certain voluntary product recalls", fill: "#c3b091"},
{source: "13: certain voluntary product recalls", target: "13: physician notifications", fill: "#c3b091"},
{source: "13: second half", target: "16: While Guidant ", fill: "#e4d00a"},
{source: "16: While Guidant ", target: "16: regaining market", fill: "#e4d00a"},
{source: "16: regaining market", target: "16: devices there", fill: "#e4d00a"},
{source: "16: devices there", target: "16: sales will return", fill: "#e4d00a"},
{source: "16: sales will return", target: "16: communications", fill: "#e4d00a"},
{source: "16: communications", target: "16: things customer", fill: "#e4d00a"},
{source: "16: things customer", target: "16: perceptions", fill: "#e4d00a"},
{source: "16: perceptions", target: "16: recently launched products", fill: "#e4d00a"},
{source: "16: recently launched products", target: "16: regulatory", fill: "#e4d00a"},
{source: "16: regulatory", target: "16: competitive developments", fill: "#e4d00a"},
{source: "16: While Guidant ", target: "28: marketing approval", fill: "#d9603b"},
{source: "28: marketing approval", target: "28: clearance from", fill: "#d9603b"},
{source: "28: clearance from", target: "28: enhancements", fill: "#d9603b"},
{source: "28: enhancements", target: "28: modifications", fill: "#d9603b"},
{source: "28: modifications", target: "28: significant", fill: "#d9603b"},
{source: "28: significant", target: "28: of Contents ", fill: "#d9603b"},
{source: "28: of Contents ", target: "28: expenditure", fill: "#d9603b"},
{source: "28: expenditure", target: "28: involve rigorous preclinical", fill: "#d9603b"},
{source: "28: involve rigorous preclinical", target: "28: clinical testing", fill: "#d9603b"},
{source: "28: clinical testing", target: "28: limitations on", fill: "#d9603b"},
{source: "28: limitations on", target: "28: indicated uses", fill: "#d9603b"},
{source: "28: marketing approval", target: "50: litigation", fill: "#3eb489"},
{source: "50: litigation", target: "50: disruptive", fill: "#3eb489"},
{source: "50: litigation", target: "68: liability", fill: "#e9d66b"},
{source: "68: liability", target: "68: litigation", fill: "#e9d66b"},
{source: "68: litigation", target: "68: shareholder derivative suits may", fill: "#e9d66b"},
{source: "68: shareholder derivative suits may", target: "68: adversely impact", fill: "#e9d66b"},
{source: "68: adversely impact", target: "68: financial condition", fill: "#e9d66b"},
{source: "68: financial condition", target: "68: operations", fill: "#e9d66b"},
{source: "68: liability", target: "94: devote continued efforts", fill: "#062a78"},
{source: "94: devote continued efforts", target: "94: financial resources", fill: "#062a78"},
{source: "94: financial resources", target: "94: scientifically advanced technologies", fill: "#062a78"},
{source: "94: scientifically advanced technologies", target: "94: products apply", fill: "#062a78"},
{source: "94: products apply", target: "94: technologies costeffectively across product lines", fill: "#062a78"},
{source: "94: technologies costeffectively across product lines", target: "94: markets attract", fill: "#062a78"},
{source: "94: markets attract", target: "94: technologies", fill: "#062a78"},
{source: "94: technologies", target: "94: skilled development personnel", fill: "#062a78"},
{source: "94: skilled development personnel", target: "94: regulatory", fill: "#062a78"},
{source: "94: regulatory", target: "94: reimbursement", fill: "#062a78"},
{source: "94: reimbursement", target: "94: successfully manufacture", fill: "#062a78"},
{source: "94: devote continued efforts", target: "START_HERE", fill: "#062a78"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Implantable_cardioverter-defibrillator">Implantable cardioverter-defibrillator</a></td>
      <td>An implantable cardioverter-defibrillator (ICD) or automated implantable cardioverter defibrillator (AICD) is a device implantable inside the body, able to perform defibrillation, and depending on the type, cardioversion and pacing of the heart. The ICD is the first-line treatment and prophylactic therapy for patients at risk for sudden cardiac death due to ventricular fibrillation and ventricular tachycardia."AICD" was trademarked by the Boston Scientific corporation, so the more generic "ICD" is preferred terminology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defibrillation">Defibrillation</a></td>
      <td>Defibrillation is a treatment for life-threatening cardiac dysrhythmias, specifically ventricular fibrillation (VF) and non-perfusing ventricular tachycardia (VT). A defibrillator delivers a dose of electric current (often called a counter-shock) to the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automated_external_defibrillator">Automated external defibrillator</a></td>
      <td>An automated external defibrillator (AED) is a portable electronic device that automatically diagnoses the life-threatening cardiac arrhythmias of ventricular fibrillation (VF) and pulseless ventricular tachycardia, and is able to treat them through defibrillation, the application of electricity which stops the arrhythmia, allowing the heart to re-establish an effective rhythm.\nWith simple audio and visual commands, AEDs are designed to be simple to use for the layperson, and the use of AEDs is taught in many first aid, certified first responder, and basic life support (BLS) level cardiopulmonary resuscitation (CPR) classes.The portable version of the defibrillator was invented in the mid-1960s by Frank Pantridge in Belfast, Northern Ireland and the first automatic, public use, defibrillator was produced by the Cardiac Resussitation Company in the late-1970s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Morton_Mower">Morton Mower</a></td>
      <td>Morton Maimon Mower (January 31, 1933 – April 25, 2022) was an American cardiologist specializing in electrophysiology and the co-inventor of the automatic implantable cardioverter defibrillator. He served in several professional capacities at Sinai Hospital and Cardiac Pacemakers Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_cardiac_pacemaker">Artificial cardiac pacemaker</a></td>
      <td>A cardiac pacemaker (or artificial pacemaker, so as not to be confused with the natural pacemaker of the heart) is a medical device that generates electrical impulses delivered by electrodes to cause the heart muscle chambers (the upper, or atria and/or the lower, or ventricles) to contract and therefore pump blood. By doing so, this device replaces and/or regulates the function of the electrical conduction system of the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cardiac_monitoring">Cardiac monitoring</a></td>
      <td>Cardiac monitoring generally refers to continuous or intermittent monitoring of heart activity, generally by electrocardiography, with assessment of the patient's condition relative to their cardiac rhythm. It is different from hemodynamic monitoring, which monitors the pressure and flow of blood within the cardiovascular system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_device">Medical device</a></td>
      <td>A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_technology">Regulatory technology</a></td>
      <td>Regulatory technology, Abrv: regtech, is a new technology that uses information technology to enhance regulatory and compliance processes. Regtech expands across all industries, including: financial services, banking, technology, retail, gaming and healthcare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Multidistrict_litigation">Multidistrict litigation</a></td>
      <td>In United States law, multidistrict litigation (MDL) refers to a special federal legal procedure designed to speed the process of handling complex cases, such as air disaster litigation or complex product liability suits.\n\n\n== Description ==\nMDL cases occur when "civil actions involving one or more common questions of fact are pending in different districts." In order to efficiently process cases that could involve hundreds (or thousands) of plaintiffs in dozens of different federal courts that all share common issues, the Judicial Panel on Multidistrict Litigation (JPML) decides whether cases should be consolidated under MDL, and if so, where the cases should be transferred.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vexatious_litigation">Vexatious litigation</a></td>
      <td>Vexatious litigation is legal action which is brought  solely to harass or subdue an adversary. It may take the form of a primary frivolous lawsuit or may be the repetitive, burdensome, and unwarranted filing of meritless motions in a matter which is otherwise a meritorious cause of action.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Review_of_Litigation">The Review of Litigation</a></td>
      <td>The Review of Litigation (TROL) is a law journal established in 1980 at the University of Texas School of Law to serve as "a national forum of interchange of academic and practical discussion of various aspects of litigation." The journal publishes articles on "topics related to procedure, evidence, trial and appellate advocacy, alternative dispute resolution, and often-litigated substantive law."The journal publishes four issues annually, one of which is a symposium issue published in collaboration with the litigation section of American Association of Law Schools. Past topics have included mass torts and conflicts of interest.The journal is often cited in published court opinions, and is the most cited law journal in the category "Civil Litigation and Dispute Resolution" in the Washington &amp; Lee Law School law journal rankings as of 2020.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abdullahi_v._Pfizer,_Inc.">Abdullahi v. Pfizer, Inc.</a></td>
      <td>The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the pharmaceutical company Pfizer in 1996 in Kano, Nigeria, during an epidemic of meningococcal meningitis. To test its new antibiotic, trovafloxacin (Trovan), Pfizer gave 100 children trovafloxacin, while another 100 received the gold-standard anti-meningitis treatment, ceftriaxone, a cephalosporin antibiotic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GUIDANT CORP      ITEM 1A  Risk Factors       In  addition to the other information contained in this Form 10-K, the     <font color="blue">following risk factors should</font> be considered <font color="blue">carefully</font> in evaluating our     business</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font>, or results of <font color="blue"><font color="blue">operations</font> could</font>     be <font color="blue">materially <font color="blue">adversely</font> <font color="blue">affected by</font></font> any of these risks</td>
    </tr>
    <tr>
      <td>Please note that     <font color="blue"><font color="blue">additional</font> risks</font> not <font color="blue">presently known</font> to the Company or that <font color="blue">the Company     </font>currently deems <font color="blue">immaterial may also impair</font> its business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>required approvals and satisfying closing <font color="blue"><font color="blue">conditions</font> may delay</font> or     <font color="blue">prevent <font color="blue">completion</font></font> of our <font color="blue">merger with</font> <font color="blue">Boston Scientific Corporation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of the merger is <font color="blue">conditioned upon</font> the receipt of all material     <font color="blue">government</font>al <font color="blue">authorization</font>s, consents, orders and approvals, including the     expiration  or  <font color="blue">termination</font>  of the <font color="blue">applicable waiting period</font>, and any     extension   of   the   waiting  period,  under  the  Hart-Scott-Rodino     Antitrust Improvements Act of 1976, as amended, and approval by the European     Commission under <font color="blue">European Commission </font><font color="blue">merger <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>While the merger     <font color="blue">agreement</font> requires certain <font color="blue">divestitures</font>, including the divestiture of our     vascular <font color="blue">intervention</font> and <font color="blue">endovascular</font> solutions business, <font color="blue">and the <font color="blue">Abbott     </font></font><font color="blue">transaction</font>  <font color="blue">agreement</font>  has  <font color="blue">been <font color="blue">entered into</font></font> in order to effect that     <font color="blue">divestiture prior</font> to the merger, these consents, orders and <font color="blue">approvals may</font>     <font color="blue">impose <font color="blue">conditions</font> on</font>, or require <font color="blue">divestitures</font> relating to, the divisions,     <font color="blue">operations</font> or assets in addition to the Abbott <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">conditions</font>     or <font color="blue">divestitures</font> may jeopardize or <font color="blue">delay <font color="blue">completion</font></font> of the Abbott <font color="blue">transaction</font>     or  the  merger  or  may reduce the anticipated benefits of the <font color="blue">Abbott     </font><font color="blue">transaction</font> or the merger</td>
    </tr>
    <tr>
      <td>Further, no assurance can be given that the     required  consents and approvals will be obtained or that the required     <font color="blue">conditions</font> to closing will be satisfied, and, if all required consents and     approvals are obtained and the <font color="blue">conditions</font> are satisfied, no assurance can be     given as to the terms, <font color="blue">conditions</font> and timing of the approvals or that they     <font color="blue">will satisfy</font> the terms of the merger <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">completion</font> of     the merger is <font color="blue">conditioned on</font> the absence of <font color="blue">certain restraining orders</font> or     <font color="blue">injunctions</font> by judgment, court order or law that <font color="blue">would restrain</font> or prohibit     <font color="blue">consummation</font> of the merger</td>
    </tr>
    <tr>
      <td>We are subject to recent claims related to the     merger from plaintiffs seeking an injunction to prohibit <font color="blue">consummation</font> of the     merger and other relief including <font color="blue">monetary damages</font></td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of the merger     is also <font color="blue">conditioned upon</font> approval of the <font color="blue">transaction</font> by the <font color="blue">shareholder</font>s of     both Guidant and BSC                                         10       _________________________________________________________________    [47]Table of <font color="blue">Contents       </font>Since  June  of 2005, we have issued a number of product <font color="blue">advisories</font> to     physicians  <font color="blue">concerning</font>  our <font color="blue">defibrillator</font> and <font color="blue">pacemaker systems</font> due to     reported adverse events and <font color="blue"><font color="blue">malfunction</font>s</font> that have <font color="blue">adversely</font> impacted our     sales and market share and could continue to have an adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Since  June  of 2005, we have issued a number of product <font color="blue">advisories</font> to     physicians  <font color="blue">concerning</font>  our <font color="blue">defibrillator</font> and <font color="blue">pacemaker systems</font> due to     reported adverse events and <font color="blue"><font color="blue">malfunction</font>s</font> described in more detail in Item 7</td>
    </tr>
    <tr>
      <td>Sales during the <font color="blue">second half</font> of 2005 decreased 14prca compared to the same     period  in  2004,  primarily  due to the impact of <font color="blue">various implantable</font>     <font color="blue">defibrillator</font> and <font color="blue">pacemaker system field actions</font> that occurred in 2005,     including <font color="blue">certain voluntary <font color="blue">product recalls</font></font> and <font color="blue">physician notifications</font>     (2005 product <font color="blue">communications</font>)</td>
    </tr>
    <tr>
      <td>The 2005 product <font color="blue">communications</font> included     Guidant’s decision announced on June 24, 2005 to <font color="blue">temporarily stop selling</font>     Guidant’s leading <font color="blue">defibrillator</font> systems, which were returned to the market     <font color="blue">beginning on</font> August 2, 2005</td>
    </tr>
    <tr>
      <td>The impact of the 2005 product <font color="blue">communications</font>     resulted  in  <font color="blue">Guidant  </font>having  a  lower  market  share for implantable     <font color="blue">defibrillator</font> and <font color="blue">pacemaker systems</font> for the <font color="blue">second half</font> of 2005 compared to     the  <font color="blue">same period</font> in the prior year</td>
    </tr>
    <tr>
      <td><font color="blue">While Guidant </font>has made progress in     <font color="blue">regaining market</font> share and sales of these devices, there can be no assurance     as  to when, or if, our market share and <font color="blue">sales will return</font> to pre-2005     product  <font color="blue">communications</font>  levels  due  to, among other things, customer     <font color="blue"><font color="blue">perception</font>s</font>  of  the 2005 product <font color="blue">communications</font>, market <font color="blue">acceptance</font> of     <font color="blue">recently launched products</font>, and <font color="blue">regulatory</font> and <font color="blue"><font color="blue">competitive</font> <font color="blue">development</font>s</font></td>
    </tr>
    <tr>
      <td>If     we  are  unable  to  <font color="blue">regain market</font> share and sales for our implantable     <font color="blue">defibrillator</font> and <font color="blue">pacemaker systems</font> or we do not <font color="blue">regain market</font> share and     sales on a <font color="blue">timely basis</font>, these <font color="blue">events could continue</font> to <font color="blue">adversely</font> affect our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance  that  we  will  not  have product <font color="blue">communications</font> <font color="blue">concerning</font>     <font color="blue">defibrillator</font>  and <font color="blue">pacemaker systems</font> in the future or that any product     <font color="blue">communications</font> would not have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  FDA,  the  US  Department of Justice, the Securities and Exchange     Commission  (SEC) and various state agencies are conducting, and other     <font color="blue">government</font>al entities may commence, <font color="blue">investigations</font> of Guidant in <font color="blue">connection</font>     with our 2005 product <font color="blue">communications</font> <font color="blue">which could</font> have an adverse effect on     our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA, the US Department of Justice, the SEC and various state agencies     are conducting, and other <font color="blue">government</font>al entities may commence, <font color="blue">investigations</font>     of Guidant in <font color="blue">connection</font> with our 2005 product <font color="blue">communications</font> as described     in  more  detail in Item 7</td>
    </tr>
    <tr>
      <td>While we are <font color="blue">cooperating with officials</font> in     <font color="blue">connection</font>  with  these  <font color="blue">investigations</font>,  we <font color="blue">cannot predict</font> when these     <font color="blue">investigations</font> will be resolved, the outcome of these <font color="blue">investigations</font> or     their  impact  on  our  business</td>
    </tr>
    <tr>
      <td>An  <font color="blue">adverse outcome</font> in any of these     <font color="blue">investigations</font> could include the <font color="blue">commencement</font> of civil and/or criminal     <font color="blue">proceedings</font>  involving  substantial fines, penalties and injunctive or     <font color="blue">administrative</font>  remedies,  including  our  exclusion  from  <font color="blue">government</font>     <font color="blue"><font color="blue">reimbursement</font> programs</font></td>
    </tr>
    <tr>
      <td>Additionally, if these <font color="blue">investigations</font> continue over     a long period of time, they <font color="blue">could divert</font> the attention of our <font color="blue">management</font>     from  the  day-to-day  <font color="blue">operations</font>  of our business, <font color="blue">impose <font color="blue">significant</font></font>     <font color="blue">administrative</font> burdens on us and result in <font color="blue"><font color="blue">additional</font> compliance</font> or other     costs</td>
    </tr>
    <tr>
      <td>These potential consequences, as well as any <font color="blue">adverse outcome</font> from any     of  these  <font color="blue">investigations</font>, could have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject to extensive domestic and foreign medical device regulation     <font color="blue">which may impede</font> or hinder the approval process for our products and, in     some cases, may not ultimately result in approval or may result in the     recall or seizure of <font color="blue"><font color="blue">previously</font> approved products</font></td>
    </tr>
    <tr>
      <td>Our products, <font color="blue">development</font> activities and <font color="blue"><font color="blue">manufacturing</font> processes</font> are subject     to extensive and <font color="blue">rigorous regulation by</font> the FDA pursuant to the Federal     Food,  Drug, and Cosmetic Act (the FDC Act), <font color="blue">by comparable agencies</font> in     <font color="blue">foreign countries</font>, and by other <font color="blue">regulatory</font> agencies and <font color="blue">governing bodies</font></td>
    </tr>
    <tr>
      <td>Under the FDC Act, <font color="blue"><font color="blue">medical devices</font> must</font> receive FDA clearance or approval     before they can be <font color="blue">commercially</font> marketed in the US In addition, most major     markets for <font color="blue"><font color="blue">medical devices</font> outside</font> the US require clearance, approval or     <font color="blue">compliance with certain standards</font> before a product can be <font color="blue">commercially</font>     marketed</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">marketing approval</font> or <font color="blue">clearance from</font> the     FDA for <font color="blue">new products</font>, or with respect to <font color="blue">enhancements</font> or <font color="blue">modifications</font> to     existing products could:         •  take a <font color="blue">significant</font> period of time;                                         11       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>    •  require the <font color="blue">expenditure</font> of substantial resources;         •  involve rigorous pre-clinical and <font color="blue">clinical testing</font>;         •  require changes to the products; and         •  result in <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> of the product</td>
    </tr>
    <tr>
      <td>Even after products have received <font color="blue">marketing approval</font> or clearance, product     approvals and <font color="blue"><font color="blue">clearances</font> by</font> the FDA can be <font color="blue">withdrawn due</font> to failure to     comply with <font color="blue">regulatory</font> standards or the occurrence of <font color="blue">unforeseen problems</font>     <font color="blue">following initial approval</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will receive     the required <font color="blue"><font color="blue">clearances</font> from</font> the FDA for <font color="blue">new products</font> or <font color="blue">modifications</font> to     existing products on a <font color="blue">timely basis</font> or that any FDA <font color="blue">approval will</font> not be     <font color="blue">subsequently withdrawn</font></td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of <font color="blue"><font color="blue">previously</font> unknown problems with</font>     a product or <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font> could</font> result in fines, delays or <font color="blue">suspensions</font> of     <font color="blue">regulatory</font>  <font color="blue">clearances</font>,  seizures  or  recalls  of products, operating     restrictions and/or criminal prosecution</td>
    </tr>
    <tr>
      <td>The failure to receive product     <font color="blue">approval clearance on</font> a <font color="blue">timely basis</font>, <font color="blue">suspensions</font> of <font color="blue">regulatory</font> <font color="blue">clearances</font>,     seizures or recalls of products or the withdrawal of <font color="blue">product approval by</font> the     FDA  could  have  a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not meet <font color="blue">regulatory</font> quality standards applicable to our <font color="blue">manufacturing</font>     processes, <font color="blue">which could</font> have an adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a device <font color="blue"><font color="blue">manufacture</font>r</font>, we are required to register with the FDA and are     subject to periodic inspection by the FDA for compliance with the FDA’s     Quality System Regulation (QSR) <font color="blue">requirements</font>, which require <font color="blue"><font color="blue">manufacture</font>r</font>s of     <font color="blue">medical devices</font> to adhere to <font color="blue">certain <font color="blue">regulations</font></font>, including testing, quality     control and <font color="blue">documentation procedures</font></td>
    </tr>
    <tr>
      <td>In addition, the federal Medical     Device Reporting <font color="blue">regulations</font> require us to provide information to the FDA     <font color="blue">whenever there</font> is evidence that <font color="blue">reasonably</font> suggests that a device may have     caused or contributed to a death or <font color="blue">serious injury</font> or, if a <font color="blue">malfunction</font> were     to occur, could cause or contribute to a death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance     </font>with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> is subject to <font color="blue">continual review</font> and     is <font color="blue">rigorously monitored through periodic inspections by</font> the FDA In the     European  Community, we are required to maintain certain International     Organization for Standardization (ISO) <font color="blue">certifications</font> in order to sell our     products and must undergo periodic inspections by notified bodies to obtain     and maintain these <font color="blue">certifications</font></td>
    </tr>
    <tr>
      <td>In that regard, we are currently taking <font color="blue">remedial action</font> in response to     <font color="blue">certain <font color="blue">deficiencies</font></font> of our <font color="blue">manufacturing</font> <font color="blue">quality systems</font> as cited in the     FDA <font color="blue">warning letter</font> to us</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">December </font></font>23, 2005, Guidant received an FDA     <font color="blue">warning letter</font> citing <font color="blue">certain <font color="blue">deficiencies</font></font> with respect to our <font color="blue">manufacturing</font>     <font color="blue">quality systems</font> and record keeping procedures in our CRM <font color="blue">facility</font> in St</td>
    </tr>
    <tr>
      <td>The  FDA  <font color="blue">warning letter</font> resulted from an extensive     inspection  by  the  FDA of these CRM <font color="blue">facilities</font> that was completed on     <font color="blue">September </font>1,  2005  and  resulted  in  a notice <font color="blue">citing <font color="blue">observation</font>s</font> of     non-compliance</td>
    </tr>
    <tr>
      <td>We received a follow-up letter from the FDA dated January 5,     2006</td>
    </tr>
    <tr>
      <td>As stated in the FDA <font color="blue">warning letter</font>, until the <font color="blue">deficiencies</font> identified     in the letter have <font color="blue">been corrected</font>, the FDA may not <font color="blue">grant requests by us</font> for     <font color="blue">exportation</font>  <font color="blue">certificates</font> to foreign <font color="blue">government</font>s or approve pre-market     <font color="blue">submissions</font> for our class III devices to which the <font color="blue">deficiencies</font> described     are  <font color="blue">reasonably</font> related</td>
    </tr>
    <tr>
      <td>A further FDA inspection of this <font color="blue">facility</font> was     <font color="blue">conducted between</font> <font color="blue">December </font>15, 2005 and <font color="blue">February </font>9, 2006 and resulted in one     <font color="blue">observation</font></td>
    </tr>
    <tr>
      <td>While we are working with the FDA to resolve these issues, this     work has required and will continue to require the <font color="blue">dedication</font> of <font color="blue">significant</font>     internal and external resources and there can be <font color="blue">no assurances</font> regarding the     length of time it will take to resolve these issues, if at all</td>
    </tr>
    <tr>
      <td>In addition,     if the <font color="blue">remedial action</font>s taken by us are not satisfactory to the FDA, we may     be unable to obtain pre-approval clearance by the FDA for certain devices or     <font color="blue">authorization</font> to sell certain devices to overseas markets</td>
    </tr>
    <tr>
      <td>We may face     <font color="blue">enforcement actions</font> in <font color="blue">connection</font> with these FDA <font color="blue">communications</font>, including     injunctive  relief and <font color="blue">civil fines</font></td>
    </tr>
    <tr>
      <td>If we fail to adhere to <font color="blue">QSR or ISO     </font><font color="blue">requirements</font>, this <font color="blue">could delay production</font> of our products and lead to fines,     <font color="blue"><font color="blue">difficult</font>ies</font>  in  obtaining  <font color="blue">regulatory</font>  <font color="blue">clearances</font>,  recalls or other     consequences, <font color="blue">which could</font> in turn have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In June 2003, we <font color="blue">entered into</font> a five-year <font color="blue">Corporate Integrity Agreement </font>with     the office of <font color="blue">Inspector General of HHS </font>relating to the resolution of the     ANCURE matter <font color="blue">further described</font> in Item 8, Note 16 to the <font color="blue">consolidated</font>     <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">enforcement actions</font> (including any action     with  respect  to  our  Corporate Integrity Agreement) could result in     <font color="blue">injunctions</font>, payment of royalties or other damages, or fines or penalties</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Pending and future patent <font color="blue">litigation</font> could be costly and <font color="blue">disruptive</font> to our     business</td>
    </tr>
    <tr>
      <td>We  operate  in  an industry that is susceptible to <font color="blue">significant</font> patent     <font color="blue">litigation</font> and, in <font color="blue">recent years</font>, it has <font color="blue">been common</font> for companies in the     medical  device industry to <font color="blue">aggressively challenge</font> the rights of other     companies to prevent the marketing of new devices</td>
    </tr>
    <tr>
      <td>We are currently the     subject of various patent <font color="blue">litigation</font> <font color="blue">proceedings</font> as described in more detail     in Item 8, Note 16 to the <font color="blue">consolidated</font> <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual     </font>property <font color="blue">litigation</font> is expensive, complex and lengthy and its outcome is     <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>Any pending or future patent <font color="blue">litigation</font> may result in     <font color="blue">significant</font> royalty or other payments or <font color="blue">injunctions</font> that can prevent the     sale of products and may <font color="blue">significant</font>ly divert the attention of our technical     and  <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>In the event our right to market any of our     products is <font color="blue">successfully challenged</font>, and if we fail to obtain a required     license or are unable to <font color="blue">design around</font> a patent, our business, financial     condition and results of <font color="blue"><font color="blue">operations</font> could</font> be materially <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We may not be able to effectively protect our <font color="blue"><font color="blue">intellectual</font> property rights</font>     <font color="blue">which could</font> have an adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patents  </font>and other <font color="blue">proprietary</font> rights are and will be essential to our     business, and our ability to <font color="blue">compete effectively with</font> other <font color="blue">companies will</font>     be <font color="blue">dependent upon</font> the <font color="blue">proprietary</font> nature of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We rely upon     trade secrets, know-how, continuing <font color="blue">technological</font> innovations and licensing     <font color="blue">opportunities</font> to develop, maintain and strengthen our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>We pursue a policy of <font color="blue">generally</font> obtaining patent protection in both the US     and abroad, where <font color="blue">commercially</font> <font color="blue">advantageous</font>, for patentable subject matter     in our <font color="blue">proprietary</font> devices and also attempt, and will attempt, to review     third-party patents and patent <font color="blue">applications</font> to the <font color="blue">extent publicly available</font>     to develop an effective patent strategy, avoid infringement of third-party     patents, identify licensing <font color="blue">opportunities</font> and monitor the patent claims of     others</td>
    </tr>
    <tr>
      <td>We currently own numerous US and foreign patents and have numerous     patent <font color="blue">applications</font> pending</td>
    </tr>
    <tr>
      <td>We also are party to various license <font color="blue">agreement</font>s     pursuant  to  which  patent  rights  have  been obtained or granted in     <font color="blue">consideration</font> for cash, cross-licensing rights or <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>No     assurance can be made that any pending or future patent <font color="blue">applications</font> will     result in <font color="blue">issued patents</font>, that any current or <font color="blue">future patents issued</font> to, or     <font color="blue">licensed by us will</font> not be challenged, invalidated or <font color="blue">circumvented by</font> our     <font color="blue">competitors</font>, or that our <font color="blue">patents will</font> not be <font color="blue">found invalid</font></td>
    </tr>
    <tr>
      <td>We may have to take <font color="blue">legal action</font> in the future to enforce our patents, trade     secrets or know-how against others</td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action</font> of that type could be     costly and time consuming to us and <font color="blue">no assurances</font> can be made that any     <font color="blue">lawsuit will</font> be successful</td>
    </tr>
    <tr>
      <td>We are <font color="blue">generally</font> involved as both a plaintiff     and a <font color="blue">defendant</font> in a number of <font color="blue">patent infringement</font> and other <font color="blue">intellectual</font>     property-related actions</td>
    </tr>
    <tr>
      <td>The invalidation of <font color="blue">key patents</font> or <font color="blue">proprietary</font>     rights that we own, or an <font color="blue">unsuccessful outcome</font> in lawsuits, in which we are     a <font color="blue">defendant</font>, to protect our <font color="blue">intellectual</font> property, could have a material     adverse  effect  on  our  business,  <font color="blue">financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>(See Item 8, Note 16 to the <font color="blue">consolidated</font> <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>)       Pending and future product <font color="blue">liability</font> claims and other <font color="blue">litigation</font>, including     private  securities  <font color="blue">litigation</font>  and <font color="blue">shareholder</font> <font color="blue">derivative suits</font>, may     <font color="blue">adversely</font> impact our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>,     reputation and ability to attract and retain customers</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">manufacture</font> and marketing of <font color="blue">medical devices</font> of the types that     we produce entail an <font color="blue">inherent risk</font> of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Many of the     <font color="blue">medical devices</font> that we <font color="blue">manufacture</font> and sell are designed to be implanted in     the human body for <font color="blue">long periods</font> of time or <font color="blue">indefinitely</font></td>
    </tr>
    <tr>
      <td>A number of factors     could result in an <font color="blue">unsafe condition</font> or injury to, or death of, a patient     with  respect  to these or other products that we <font color="blue">manufacture</font> or sell,     including  component  failures, <font color="blue">manufacturing</font> flaws, design defects or     inadequate  <font color="blue">disclosure</font>  of  product-related  risks  or product-related     information</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> result in product <font color="blue">liability</font> claims, a     recall, or a <font color="blue">safety alert</font> relating to one or more of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">liability</font> claims may be <font color="blue">brought by individuals</font> or <font color="blue">by groups seeking</font> to     represent a class</td>
    </tr>
    <tr>
      <td>We are currently the subject of numerous product <font color="blue">liability</font> claims and other     <font color="blue">litigation</font>,  including  private  securities <font color="blue">litigation</font> and <font color="blue">shareholder</font>     <font color="blue">derivative suits</font> relating to such product <font color="blue">liability</font> claims as described in     more detail in Item 8, Note 16 to the <font color="blue">consolidated</font> <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>The     outcome of <font color="blue">litigation</font>, particularly class <font color="blue">action lawsuits</font>, is <font color="blue">difficult</font> to     assess  or  quantify</td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>in these types of lawsuits often seek     recovery of very large or <font color="blue">indeterminate</font> amounts, including not only actual     damages, but also punitive damages</td>
    </tr>
    <tr>
      <td>The magnitude of the                                         13       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font><font color="blue">potential loss</font> relating to these <font color="blue">lawsuits may remain unknown</font> for substantial     periods  of  time</td>
    </tr>
    <tr>
      <td>In addition, the cost to <font color="blue">defend against</font> any future     <font color="blue">litigation</font>  may  be <font color="blue">significant</font> and it may divert the attention of our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>As  a  result of economic factors currently impacting the     insurance industry, <font color="blue">meaningful</font> product <font color="blue">liability</font> insurance coverage has     become unavailable due to its <font color="blue">economically</font> <font color="blue">prohibitive</font> cost</td>
    </tr>
    <tr>
      <td>As a result,     beginning  <font color="blue">September </font>1,  2005, we are largely self-insured for product     <font color="blue">liability</font>  claims</td>
    </tr>
    <tr>
      <td>The decision to become self-insured does not affect     <font color="blue">coverage with respect</font> to claims made under previous policies which, most     recently, contained substantial self-insurance retentions; however, certain     product <font color="blue">liability</font> claims may be, and in <font color="blue">certain circumstances</font>, have been,     <font color="blue">contested by</font> the carrier</td>
    </tr>
    <tr>
      <td>The absence of third-party insurance coverage     increases  our  <font color="blue">potential exposure</font> to <font color="blue">unanticipated</font> claims and adverse     <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims, <font color="blue">product recalls</font> and other <font color="blue">litigation</font> in     the future, regardless of their ultimate outcome, could have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font> and may not be able to keep pace with the rapid     <font color="blue">technological</font> changes in the <font color="blue">medical devices</font> industry <font color="blue">which could</font> have an     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The medical device market is <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>We encounter <font color="blue">significant</font>     <font color="blue">competition</font>  across  our <font color="blue">product lines</font> and in <font color="blue">each market</font> in which our     products are <font color="blue">sold from various medical</font> device companies, some of which may     have <font color="blue">greater financial</font> and <font color="blue">marketing resources than</font> we do</td>
    </tr>
    <tr>
      <td>Our primary     <font color="blue">competitors</font> for implantable cardiac rhythm <font color="blue">management</font> devices are Medtronic     and St</td>
    </tr>
    <tr>
      <td>Guidant’s primary <font color="blue">competitors</font> for <font color="blue">vascular disease products</font>     include Abbott, BSC, J&amp;J and Medtronic</td>
    </tr>
    <tr>
      <td>We face a number of <font color="blue">additional</font>     <font color="blue">competitors</font> with respect to Guidant’s other products</td>
    </tr>
    <tr>
      <td>In addition, we also     face <font color="blue">competition</font> from a wide range of companies that sell a single or a     limited  number of <font color="blue"><font color="blue">competitive</font> products</font> or <font color="blue">which <font color="blue">participate</font> only</font> in a     <font color="blue">specific market</font> segment, as well as from non-medical device companies,     including pharmaceutical companies, which may offer non-surgical alternative     therapies for disease states intended to be <font color="blue">treated using</font> our products</td>
    </tr>
    <tr>
      <td>Additionally,  the medical device market is <font color="blue">characterized</font> by extensive     research and <font color="blue">development</font>, and rapid <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by     other companies of new or improved products, processes or <font color="blue">technologies</font>, in     particular in the <font color="blue">drug eluting stent</font> or CRM markets, may make our products     or <font color="blue">proposed products obsolete</font> or <font color="blue">less <font color="blue">competitive</font></font> and <font color="blue">may negatively impact</font>     our revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">devote continued efforts</font> and <font color="blue">financial resources</font> to develop     or acquire scientifically advanced <font color="blue">technologies</font> and products, apply our     <font color="blue">technologies</font> cost-effectively across <font color="blue">product lines</font> and markets, attract and     retain skilled <font color="blue">development</font> personnel, obtain patent and other protection for     our <font color="blue">technologies</font> and products, obtain required <font color="blue">regulatory</font> and <font color="blue">reimbursement</font>     approvals and successfully <font color="blue">manufacture</font> and market our products</td>
    </tr>
    <tr>
      <td>If we fail     to  develop <font color="blue">new products</font> or <font color="blue">enhance existing products</font>, it could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font> is <font color="blue">dependent upon</font> the <font color="blue">development</font> of <font color="blue">new products</font>, which     requires  <font color="blue">significant</font>  research  and  <font color="blue">development</font>, <font color="blue">clinical trials</font> and     <font color="blue">regulatory</font> approvals, all of which are very expensive and time-consuming and     may not result in a <font color="blue">commercially</font> viable product</td>
    </tr>
    <tr>
      <td>In order to develop <font color="blue">new products</font> and improve our <font color="blue">current product offerings</font>,     we  will  focus  our  research and <font color="blue">development</font> programs largely on the     <font color="blue">development</font>  of  next-generation and <font color="blue">novel technology offerings across</font>     <font color="blue">multiple programs</font> and divisions</td>
    </tr>
    <tr>
      <td>We expect to launch our next-generation     implantable cardioverter <font color="blue">defibrillator</font> and <font color="blue">cardiac resynchronization therapy</font>     <font color="blue">defibrillator</font>  systems  devices  within the next 12 months, subject to     <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">If the SPIRIT </font>family of <font color="blue">clinical trials</font> is successful,     Guidant expects to enter the US market in <font color="blue">approximately two years</font></td>
    </tr>
    <tr>
      <td>If we are     unable to develop and launch these <font color="blue">products as</font> anticipated, our ability to     maintain or expand our positions in the stent or CRM <font color="blue">market may</font> be <font color="blue">adversely</font>     impacted,  <font color="blue">which could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a part of the <font color="blue">regulatory</font> process of obtaining marketing <font color="blue">clearance from</font>     the  FDA for <font color="blue">new products</font>, we will conduct and <font color="blue">participate</font> in numerous     <font color="blue">clinical trials</font> with a variety of study designs, patient <font color="blue">populations</font> and     trial <font color="blue">endpoints</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>or inconsistent clinical data from existing or     future <font color="blue">clinical trials</font> conducted by us, our <font color="blue">competitors</font> or third parties, or     the market’s <font color="blue">perception</font> of this clinical data, may <font color="blue">adversely</font> impact our     ability to                                         14       _________________________________________________________________    [51]Table of <font color="blue">Contents       </font>obtain <font color="blue">product approvals from</font> the FDA, our position in, and share of, the     markets in which we <font color="blue">participate</font> and our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font><font color="blue"><font color="blue">cost containment</font> pressures</font> and <font color="blue">legislative</font> or <font color="blue">administrative</font>     reforms resulting in restrictive <font color="blue">reimbursement</font> practices of third-party     payers or <font color="blue">preferences</font> for <font color="blue">alternate therapies could decrease</font> the demand for     our  products,  the prices that customers are willing to pay for those     products and the number of procedures performed using our devices, which     could  have an adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">purchased principally by hospitals</font> or physicians, which     typically bill various third-party payers, including <font color="blue">government</font>al programs     (eg, Medicare and Medicaid), <font color="blue">private insurance</font> plans and <font color="blue">managed care</font>     plans, for the <font color="blue">healthcare services provided</font> to their patients</td>
    </tr>
    <tr>
      <td>The ability     of customers to obtain appropriate <font color="blue">reimbursement</font> for their products and     <font color="blue">services <font color="blue">from private</font></font> and <font color="blue">government</font>al third-party payers is critical to the     success of medical device companies</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of <font color="blue">reimbursement</font>     <font color="blue">affects which products customers purchase</font> and the prices they are willing to     pay</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">varies from country</font> to country and can <font color="blue">significant</font>ly     impact the <font color="blue">acceptance</font> of <font color="blue">new products</font> and services</td>
    </tr>
    <tr>
      <td>After we develop a     <font color="blue">promising new product</font>, we may find limited demand for the <font color="blue">product unless</font>     <font color="blue">reimbursement</font> approval is obtained <font color="blue">from private</font> and <font color="blue">government</font>al third-party     payers</td>
    </tr>
    <tr>
      <td><font color="blue">Further  </font><font color="blue">legislative</font>  or  <font color="blue">administrative</font> reforms to the US or     <font color="blue">international</font> <font color="blue">reimbursement</font> systems in a manner that <font color="blue">significant</font>ly reduces     <font color="blue">reimbursement</font> for <font color="blue">procedures using</font> our <font color="blue">medical devices</font> or <font color="blue">denies coverage</font>     for those <font color="blue">procedures could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Major third-party payers for <font color="blue">hospital services</font> in the US and abroad continue     to work to contain <font color="blue">healthcare costs</font></td>
    </tr>
    <tr>
      <td>The introduction of <font color="blue">cost containment</font>     incentives, combined with closer scrutiny of healthcare <font color="blue">expenditure</font>s by both     <font color="blue">private health insurers</font> and employers, has resulted in <font color="blue">increased discounts</font>     and <font color="blue">contractual adjustments</font> to <font color="blue">hospital charges</font> for services performed, and     shifted <font color="blue">services between inpatient</font> and <font color="blue">outpatient settings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Initiatives </font>to     limit the increase of <font color="blue">healthcare costs</font>, including price regulation, are also     underway in several countries in which we do business</td>
    </tr>
    <tr>
      <td>Further <font color="blue">legislative</font>     or <font color="blue">administrative</font> reforms to the US or <font color="blue">international</font> <font color="blue">reimbursement</font> systems     in a manner that <font color="blue">significant</font>ly reduces <font color="blue">reimbursement</font> for <font color="blue">procedures using</font>     our <font color="blue">medical devices</font> or <font color="blue">denies coverage</font> for <font color="blue">such procedures would</font> have an     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Hospitals </font>or physicians may respond to these cost-containment     pressures by <font color="blue">substituting</font> lower cost products or other therapies for our     products</td>
    </tr>
    <tr>
      <td>Additionally, in light of our recalls, third-party payers may seek     claims and further recourse against us for the recalled <font color="blue">defibrillator</font> and     <font color="blue">pacemaker systems</font> for which we had <font color="blue">previously</font> received <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consolidation </font>in the <font color="blue"><font color="blue">healthcare industry</font> could lead</font> to demands for price     <font color="blue">concessions</font>  or to the exclusion of some <font color="blue">suppliers from certain</font> of our     <font color="blue">significant</font>  market segments <font color="blue">which could</font> have an adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The cost of healthcare has risen <font color="blue">significant</font>ly over the past decade and     <font color="blue">numerous initiatives</font> and reforms initiated by legislators, regulators and     third-party payers to curb these costs have resulted in a <font color="blue">consolidation</font>     trend in the <font color="blue">healthcare industry</font>, including hospitals</td>
    </tr>
    <tr>
      <td>This in turn has     resulted in greater pricing pressures and the exclusion of <font color="blue">certain suppliers</font>     from  important  market  segments  as  group <font color="blue">purchasing organizations</font>,     <font color="blue">independent</font>  delivery  networks  and large <font color="blue">single accounts continue</font> to     consolidate purchasing <font color="blue">decisions</font> for some of our <font color="blue">hospital customers</font></td>
    </tr>
    <tr>
      <td>We     expect that market demand, <font color="blue">government</font> regulation, third-party <font color="blue">reimbursement</font>     policies  and <font color="blue">societal pressures will continue</font> to change the worldwide     healthcare  industry, resulting in further business <font color="blue">consolidation</font>s and     <font color="blue">alliances among</font> our customers, which may reduce <font color="blue">competition</font>, exert further     <font color="blue">downward pressure on</font> the prices of our products and may <font color="blue">adversely</font> impact our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>a  portion  of  our  future  growth  is expected to come from     <font color="blue">international</font> <font color="blue">operations</font>, changes in <font color="blue">international</font> economic or <font color="blue">regulatory</font>     <font color="blue">conditions</font> could have a material <font color="blue">impact on</font> our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our revenues, costs of <font color="blue">operations</font> and <font color="blue">net income could</font> be <font color="blue">affected by</font> a     number of <font color="blue">international</font> economic or <font color="blue">regulatory</font> <font color="blue">conditions</font>, including changes     in  <font color="blue">foreign currency exchange rates</font>, changes in economic or <font color="blue">regulatory</font>     <font color="blue">conditions</font>  from  country to country, changes in a country’s political     condition, trade protection measures,                                         15       _________________________________________________________________    [52]Table of <font color="blue">Contents       </font><font color="blue">intellectual</font> property protection and other legal <font color="blue">requirements</font> and <font color="blue">local tax</font>     issues</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">international</font> markets are also being <font color="blue">affected by</font>     <font color="blue">economic pressure</font> to contain <font color="blue">reimbursement</font> levels and <font color="blue">healthcare costs</font></td>
    </tr>
    <tr>
      <td>The     trend in <font color="blue">countries around</font> the world, including Japan, toward more stringent     <font color="blue">regulatory</font> <font color="blue">requirements</font> for <font color="blue">product clearance</font>, changing <font color="blue">reimbursement</font> models     and more <font color="blue">vigorous enforcement activities</font> has <font color="blue">generally</font> caused or may cause     medical device <font color="blue"><font color="blue">manufacture</font>r</font>s to experience more uncertainty, delay, greater     risk  and <font color="blue">higher expenses</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> changes in the <font color="blue">competitive</font>,     political, legal, <font color="blue">regulatory</font>, <font color="blue">reimbursement</font> or <font color="blue">economic environment</font> where we     will conduct <font color="blue">international</font> <font color="blue">operations</font> may have a material <font color="blue">impact on</font> our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>